GLP-1

Clinical trials demonstrate that absorption of GLP-1 medications is virtually identical regardless of whether the injection is administered in the abdomen, thigh, arm, or glutes. The speaker cites this as established research-backed finding from formal clinical trials. No dosage specifics are mentioned in this context.

Repeated injections into the same anatomical site cause scar tissue accumulation, which the speaker warns will significantly reduce medication absorption. This can create a clinical picture where the GLP-1 medication appears to have stopped working, when the underlying cause is actually impaired subcutaneous absorption due to lipohypertrophy or fibrosis. No specific timeline for scar tissue development is provided.

The speaker issues a safety-oriented protocol recommendation to rotate injection sites at least weekly and maintain a minimum distance of 2 inches from the previous injection site. This is framed as a critical practice to prevent complications from repeated injections in the same location.

The speaker recommends a self-experimentation protocol of testing all four injection sites (abdomen, thigh, arm, glutes), tracking individual results, and identifying the most effective personal site. This is presented as a practical clinical recommendation to bridge the gap between population-level research and individual response.

Despite uniform absorption shown in clinical trials, the speaker reports observing significant individual variability in patient outcomes based on injection site. Some patients achieve better results injecting in the abdomen while experiencing poor results in the thigh, and vice versa. This finding is based on the speaker's clinical patient observations rather than controlled data.

The speaker identifies unresolved insulin resistance as the primary driver of weight regain after stopping GLP-1 agonists. He frames the solution as fixing the hormonal environment rather than increasing caloric restriction, suggesting that sustainable results require addressing insulin signaling — not just appetite suppression.

Dr. Jones recommends combining GLP-1 agonists with strategic fasting, high protein intake, and resistance training to fix the hormonal environment. He claims this combination quiets hunger, restores metabolic rate, and allows the body to release stored fat. No specific dosages, protein targets, or training protocols are given.

Dr. Jones positions GLP-1 receptor agonists as facilitators that make the reversal of insulin resistance dramatically easier, but warns against using them as a crutch. He claims that weight regain after stopping GLP-1s happens because the underlying insulin resistance was never addressed. No specific GLP-1 drug names (semaglutide, tirzepatide) or dosages are mentioned.

Dr. Jones outlines a three-pillar protocol for autoimmune conditions: (1) root cause functional medicine addressing gut, inflammation, nutrients, diet, and nervous system; (2) advanced tools including low-dose naltrexone, anti-inflammatory diet, and therapeutic peptides (BPC-157, KPV, Larazotide, Thymosin Alpha-1, GLP-1s); (3) medical oversight. He emphasizes that most programs only offer one or two of these pieces, and all three are needed for success.

Dr. Jones highlights GLP-1 receptor agonists (primarily metabolic drugs) as showing promising research for anti-inflammatory and immune modulating effects relevant to autoimmune patients. He positions them as part of the 'advanced metabolic tools' tier in his autoimmune protocol, distinct from their primary weight-loss/metabolic indication. No specific agents or dosages are named.

The speaker warns that skipping the foundational protocol (protein, fasting, labs) while on a GLP-1 leads to a cycle of weight loss and regain, dose escalation, and poor long-term outcomes. This is framed as the most common patient mistake with both injectable and oral GLP-1 formulations.

The speaker outlines a concurrent protocol for GLP-1 users: minimum 100g protein per day, strategic fasting (no further detail on timing/window), and targeted lab work to assess and address underlying insulin resistance. He presents these as non-negotiable for sustained results on any GLP-1 therapy.

The speaker recommends finding the lowest effective dose of any GLP-1 agonist — just enough to reduce appetite ('quiet the food chatter') — rather than escalating dose aggressively. No specific mg/mcg dosages are provided. This applies equally to oral and injectable forms.

The FDA has granted fast-track/priority designation to Eli Lilly's once-weekly oral GLP-1 pill (referred to as 'foundo,' likely orforglipron) for obesity treatment. The speaker frames this as a major shift in access — eliminating the need for injections or refrigeration. No specific efficacy data or trial results are cited in the transcript.